Growth Metrics

Sunshine Biopharma (SBFM) Assets Average (2016 - 2025)

Sunshine Biopharma (SBFM) has disclosed Assets Average for 12 consecutive years, with $31.7 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Assets Average rose 6.9% year-over-year to $31.7 million, compared with a TTM value of $31.7 million through Sep 2025, up 6.9%, and an annual FY2024 reading of $29.0 million, up 2.33% over the prior year.
  • Assets Average was $31.7 million for Q3 2025 at Sunshine Biopharma, up from $30.6 million in the prior quarter.
  • Across five years, Assets Average topped out at $41.4 million in Q3 2022 and bottomed at $1.5 million in Q1 2021.
  • Average Assets Average over 5 years is $23.3 million, with a median of $28.1 million recorded in 2023.
  • The sharpest move saw Assets Average soared 1818.4% in 2022, then plummeted 32.34% in 2023.
  • Year by year, Assets Average stood at $2.4 million in 2021, then surged by 1390.14% to $35.1 million in 2022, then dropped by 21.55% to $27.5 million in 2023, then rose by 10.22% to $30.3 million in 2024, then increased by 4.68% to $31.7 million in 2025.
  • Business Quant data shows Assets Average for SBFM at $31.7 million in Q3 2025, $30.6 million in Q2 2025, and $29.9 million in Q1 2025.